BetterLife Pharma Inc.

BetterLife Pharma Inc.

1388 views3 min read

BetterLife Files Patent for Invention of Novel Subcutaneous Implant to Prevent Drug Diversion of LSD and Other Psychedelic Drugs

BetterLife Pharma
VANCOUVER, British Columbia, April 29, 2021 -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on the development and commercialization of cutting-edge treatments for mental disorders, is pleased to announce that it has applied for patent protection of its ... Read More...
Financials312 views0 min read

Geodrill Provides Notice of 2020 Fourth Quarter and Year-End Financial Results and Conference Call

BetterLife Pharma
VANCOUVER, BC, Dec. 7, 2020 - The following issues have been halted by IIROC:Company: BetterLife Pharma Inc.CSE Symbol: BETRAll Issues: NoReason: At the request of the Company Pending NewsHalt Time (ET): 2:05 PMIIROC can make a decision to impose a temporary suspension (halt) of trading in a security of a publicly-listed company. Trading ... Read More...
52 views4 min read

BetterLife Engages Eurofins Discovery for its Next Generation Psychedelics 2-bromo-LSD FDA IND-enabling Pharmacology Studies

BetterLife Pharma
VANCOUVER, Jan. 27, 2021 -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on the development and commercialization of cutting-edge treatments in mental disorders and viral infections, announces it has entered into an agreement with Eurofins Discovery for ... Read More...
25 views4 min read

BetterLife Demonstrates 6 months Refrigerated Stability of its Proprietary Interferon Formulation to be Developed to Treat Early Stage Covid-19 Cases

BetterLife Pharma
VANCOUVER, Jan. 26, 2021 -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on the development and commercialization of cutting-edge treatments in mental disorders and viral infections, today announced it has confirmed stability of its inhalable interferon ... Read More...
17 views4 min read

BetterLife Selects CRO to Conduct Clinical Trials for AP-003 in COVID-19 Cases in Indonesia

BetterLife Pharma
VANCOUVER, Jan. 21, 2021 -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech focused on the development and commercialization of cutting-edge treatments in mental disorders and viral infections, is pleased to announce that it has engaged Equilab International to manage the ... Read More...
211 views3 min read

BetterLife Announces Formation of Next Generation Psychedelic Research Advisory Board

BetterLife Pharma
VANCOUVER, Jan. 07, 2021 -- January 7, 2021 - BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company, is pleased to announce the formation of its Next Generation Psychedelic Research Advisory Board and appointment of highly experienced Ms. Hattie Wells as its first member... Read More...
149 views3 min read

BetterLife Pharma Strengthens Board of Directors

BetterLife Pharma
VANCOUVER, Dec. 28, 2020 -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) CSE: BETR / OTCQB: BETRF / FRA: NPAU) an emerging biotech company, is pleased to announce that it has added Mr. Sergei Stetsenko to its Board of Directors to prepare for its growth phase in psychedelic medicines. Mr. Stetsenko is a financier and venture cap... Read More...
298 views4 min read

BetterLife Welcomes Psychedelic Industry Leaders to the Senior Management Team

BetterLife Pharma
VANCOUVER, Dec. 22, 2020 -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) CSE: BETR / OTCQB: BETRF / FRA: NPAU) an emerging biotech company, is pleased to announce that Patrick Kroupa and Justin Kirkland, two industry leaders in psychedelic therapeutics, have joined the Company. Mr. Kroupa and Mr. Kirkland will join the senior ma... Read More...





Make smarter investment strategies
with in-depth news reports

Join our subscribers!